# Surviving the Storm: One Young Man's Battle With Sepsis and Cardiogenic Shock

**Authors:** Samaresh C Sarkar, Ying Kristen Lau, Rhea H Kamat, Sumantra Kumar De

PMC · DOI: 10.7759/cureus.93824 · Cureus · 2025-10-04

## TL;DR

A young man with sepsis developed severe heart dysfunction but fully recovered, highlighting the reversible nature of septic cardiomyopathy.

## Contribution

This case emphasizes the reversibility of septic cardiomyopathy and underscores the need for targeted therapies.

## Key findings

- A young male with sepsis developed acute left ventricular systolic dysfunction with ejection fraction less than 10%.
- Serial imaging showed recovery with ejection fraction rising to 65% and resolving myocardial inflammation.
- Conservative management with antimicrobials resolved the underlying infection and renal abscess.

## Abstract

Septic cardiomyopathy (SCM) is a reversible myocardial dysfunction during sepsis, marked by impaired ventricular contractility and reduced ejection fraction without primary ischaemic injury. It significantly contributes to septic shock morbidity and mortality. We report a healthy young male who developed acute left ventricular systolic dysfunction after severe urosepsis from Escherichia coli bacteremia. The initial assessment revealed haemodynamic instability, lactic acidosis, and a left ventricular ejection fraction (LVEF) of less than 10%. Despite fluids and vasopressors, he progressed to cardiogenic shock requiring multiple inotropes and extracorporeal membrane oxygenation (ECMO) consideration. Serial imaging revealed cardiac recovery with LVEF rising to 65% and resolving myocardial inflammation. The infection, complicated pyelonephritis with a renal abscess, was managed conservatively with prolonged antimicrobials. SCM's pathophysiology involves inflammatory mediators, endotoxins, and mitochondrial dysfunction, causing transient systolic and diastolic impairment. Early recognition via bedside ultrasound and haemodynamic optimisation are crucial for recovery. This case highlights SCM's reversibility and the need for further research into targeted therapies.

## Linked entities

- **Diseases:** cardiogenic shock (MONDO:0800175), pyelonephritis (MONDO:0006939)

## Full-text entities

- **Diseases:** infection (MESH:D007239), myocardial dysfunction (MESH:D006331), systolic and diastolic impairment (MESH:D006337), left ventricular systolic dysfunction (MESH:D018487), pyelonephritis (MESH:D011704), Cardiogenic Shock (MESH:D012770), Sepsis (MESH:D018805), septic shock (MESH:D012772), impaired ventricular contractility (MESH:D018754), Escherichia coli bacteremia (MESH:D004927), mitochondrial dysfunction (MESH:D028361), lactic acidosis (MESH:D000140), inflammatory (MESH:D007249), ischaemic injury (MESH:D014947), renal abscess (MESH:D000038), SCM (MESH:D009202)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12584081/full.md

## Figures

11 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12584081/full.md

## References

14 references — full list in the complete paper: https://tomesphere.com/paper/PMC12584081/full.md

---
Source: https://tomesphere.com/paper/PMC12584081